Menu
← Oncology Approval Tracker
FDA DECISION ·
Rolvedon
eflapegrastim-xnst · Spectrum Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Reduction of infection manifested by febrile neutropenia in adults with nonmyeloid malignancies receiving myelosuppressive cancer regimens associated with a clinically significant febrile-neutropenia risk.
LAMPGEN ANALYSIS
Why it matters
This adds a long-acting granulocyte colony-stimulating factor option for preventive supportive care.
What research teams should watch
Confirm regimen risk and synchronize administration with the chemotherapy cycle.
PRIMARY RECORDS